• Patient-Derived Gastric Cancer Assembloids

  2026-10-10

  Shapira-Netanelov and colleagues developed a patient-derived gastric cancer assembloid model that combines matched tumor organoids with stromal cell subpopulations from the same tumor. The study shows that stromal composition can reshape gene expression and drug response, supporting more context-aware cancer biology research while leaving important questions about clinical prediction and broader validation unresolved.

• GS-441524: Mechanism, Evidence and Research Limits

  2026-10-09

  GS-441524 is an adenine nucleoside analog whose antiviral relevance depends on intracellular conversion to phosphorylated metabolites. Current evidence supports mechanistic and pharmacokinetic research, but prodrug-conversion findings in rats do not establish human clinical efficacy.

• BMN 673 and BRCA2: PARP Trapping in Context

  2026-10-09

  BMN 673, also known as Talazoparib, is a PARP1/2 inhibitor studied in the context of DNA repair deficiency and PARP–DNA complex trapping. A 2025 Nature study adds mechanistic detail by showing that BRCA2 protects RAD51 filaments from PARP inhibitor-associated PARP1 retention at homologous-recombination repair sites. This overview compares the supplier-reported pharmacology with the peer-reviewed findings, identifies conceptual applications in DNA repair deficiency targeting, and emphasizes evidence limitations, including the distinction between general PARP inhibitor mechanisms and talazoparib-specific conclusions.

• How LNP Charge and V-ATPase Shape Delivery

  2026-10-08

  A 2026 study proposes that lipid nanoparticle surface charge and target-cell V-ATPase activity jointly influence where nucleic acid delivery is functionally effective. Its in vitro and in vivo findings connect cell-state biology, organ tropism, and protein-corona composition, while also showing why nanoparticle properties alone may not explain delivery outcomes.

• Dacarbazine: Research Context and Evidence Limits

  2026-10-08

  A source-grounded overview of Dacarbazine as an antineoplastic chemotherapy drug, covering its proposed cancer DNA damage pathway, research applications, clinical context, supportive-care evidence, and important limitations in the supplied literature.

• I-BET151 in Cancer Biology: Evidence and Limitations

  2026-10-07

  I-BET151, also known as GSK1210151A, is a research compound used to investigate BET bromodomain-dependent transcription. This overview separates supplier-reported activity from published findings, explains conceptual applications in cancer biology, and examines how its evidence compares with a separate study of PDX1-associated pancreatic disease and m6A methylation.

• AO/PI Staining in Rare-Cell Research

  2026-10-07

  This overview examines the research context, interpretive value, and limitations of AO/PI Double Staining Kit readouts for cell viability, apoptosis detection, and necrosis detection, including their possible role as ancillary measurements in rare-cell studies.

• U0126-EtOH: MEK1/2 Inhibitor Evidence Guide

  2026-10-06

  U0126-EtOH is a selective MEK1/2 inhibitor used to interrogate MAPK/ERK signaling. Product documentation supports biochemical potency and reports neuroprotective and anti-inflammatory model findings, while the supplied peer-reviewed evidence mainly establishes pathway context and requires careful interpretation.

• ONX-0914 (PR-957): Evidence and Research Context

  2026-10-06

  ONX-0914, also known as PR-957, is a research compound used to investigate LMP7-containing immunoproteasomes. Evidence from airway rhinovirus research shows that LMP7 can support antiviral and anti-inflammatory defenses, highlighting why findings from autoimmune, arthritis, diabetes, and colitis models should be interpreted in a tissue- and disease-specific manner.

• Givinostat and CBS Folding in Murine Homocystinuria

  2026-10-05

  Petrosino and colleagues developed a split-fluorescent-protein reporter to identify compounds that restore folding-related recovery of the CBS I278T variant, a common cause of cystathionine beta-synthase deficiency. Their findings implicate givinostat as a lead pharmacological chaperone candidate whose effects combine CBS engagement with broader proteostasis modulation, while mouse data provide early but limited translational support.

• KRAS Phase Separation and Colon Tumor Growth

  2026-10-05

  A 2026 Cell study reports that farnesylation at KRAS C185 promotes cytoplasmic condensates that organize RCE1-dependent KRAS processing and strengthen oncogenic signaling in colon cancer. The findings connect KRAS post-translational modification, intracellular organization, tumor growth, and response to G12C inhibition, while also identifying important limits for therapeutic interpretation.

• Phosbind Acrylamide in Phosphorylation Research

  2026-10-04

  Phosbind Acrylamide is presented by its supplier as a phosphate-binding reagent for phosphorylation-sensitive protein separation. Its conceptual relevance to soybean phosphate-deficiency research is indirect: the cited study identifies a genetic and hormonal regulatory module for low-phosphate tolerance but does not establish that its proteins are phosphorylated or that Phosbind was used. This overview separates product claims from peer-reviewed findings and outlines evidence strength, research applications, and key limitations.

• IAM-LC vs LEKC for Pulmonary Drug Permeability

  2026-10-03

  The 2024 Journal of Chromatography A study provides a direct comparison of immobilised artificial membrane liquid chromatography and liposome electrokinetic capillary chromatography for biomimetic drug-partitioning analysis. Its findings indicate that LEKC better reflected apparent pulmonary permeability for the tested compounds, while IAM LC offered broader compound coverage and simpler, more automation-friendly analysis.

• LncRNA MRF, FSHR, and BMSC Osteogenesis

  2026-10-02

  A 2025 Stem Cell Research & Therapy study identifies lncRNA MRF as an inhibitory regulator of BMSC osteogenic differentiation and bone defect repair. Its findings connect MRF to FSHR-dependent cAMP–PKA–CREB signaling, providing a mechanistic framework for studying osteoporosis-related impaired bone formation.

• HCAR3 Structures Explain Agonist Selectivity

  2026-10-01

  Ye et al. combine cryo-EM structures with cAMP signaling assays to define how HCAR3 recognizes several agonists and differs from HCAR2. The work links ligand selectivity to orthosteric-pocket occupancy, aromatic contacts, and receptor-specific residues, providing a structural framework for lipid metabolism regulation without assuming that structural selectivity alone establishes therapeutic efficacy.

8403 records 1/561 page Next 12345 下5页 Last page